Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma (Q33985606)

30 July 2017

title

Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma (English)

1 reference

30 July 2017

1 reference

T Miyoshi

1

1 reference

30 July 2017

F Otsuka

2

1 reference

30 July 2017

M Takeda

3

1 reference

30 July 2017

K Inagaki

4

1 reference

30 July 2017

J Suzuki

5

1 reference

30 July 2017

T Ogura

6

1 reference

30 July 2017

I Date

7

1 reference

30 July 2017

K Hashimoto

8

1 reference

30 July 2017

H Makino

9

1 reference

30 July 2017

publication date

1 December 2004

1 reference

Journal of Endocrinological Investigation

30 July 2017

published in

1 reference

30 July 2017

volume

27

1 reference

30 July 2017

issue

11

1 reference

30 July 2017

page(s)

1055-1059

1 reference

Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

Transsphenoidal microsurgery for Cushing disease. A report of 216 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

Pituitary adenoma showing intermittent secretion of high molecular weight adrenocorticotropin without evidence of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

Cabergoline in the treatment of acromegaly: a study in 64 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

ACTH silent adenoma shrinking under cabergoline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

Successful Pregnancy after Bromocriptine Therapy in an Anovulatory Woman Complicated with Ovarian Hyperstimulation Caused by Follicle-Stimulating Hormone-Producing Plurihormonal Pituitary Microadenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345309

Dopamine agonists and pituitary tumor shrinkage

21 January 2018

1 reference

12 December 2020

Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice

1 reference

12 December 2020

Dopamine as a Prolactin (PRL) Inhibitor

1 reference

12 December 2020

Complete remission of Nelson's syndrome after 1-year treatment with cabergoline

1 reference

12 December 2020

Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas

1 reference

12 December 2020

Management of pituitary tumors

1 reference

12 December 2020

Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas

1 reference

12 December 2020

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03345309

1 reference

Dimensions Publication ID

30 July 2017

1039108939

0 references

1 reference